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Intercellular adhesion molecule-1 (ICAM-1) is a transmembrane glycoprotein and a major ligand for the integrin leukocyte function-associated antigen-1 (LFA-1). The interaction between ICAM-1 and LFA-1 plays an important role in many lymphocyte activities during inflammatory and immunological reactions. Recently, a soluble form of ICAM-1 (SICAM-1) has been detected in normal serum [ 13 and we have previously demonstrated the secretion of SICAM-1 by cytokine stimulated bladder tumour cell lines as well as its detection in the urine of patients receiving bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer 121.
Reports of a functional role for SICAM-1 are conflicting. While some have suggested that SICAM-1 can inhibit cell-cell adhesion events there are several which have failed to demonstrate this. In an attempt to elucidate a role for SICAM-1 we studied whether highly purified SICAM-1 could compete with membrane bound ICAM-1 for lymphocyte binding, thus allowing tumour cells to evade immunodetection. This was approached by isolating and characterising SICAM-1 from a variety of starting materials and determining their effect on the lymphokine-activated killer (LAK) cell-mediated cytolysis of bladder tumour cells in vitm.
Soluble ICAM-1 was isolated by immunoaffinity chromatography from normal human serum, bladder tumour cell culture supernatants and the urine of patients receiving BCG immunotherapy for bladder cancer on two different anti-ICAM-1 monoclonal antibody (MAb) columns. Figure 1 shows that the SICAM-1 isolated from all three sources resolved as a single diffuse band of molecular mass 80 to 90 kDa under both nonreducing and reducing conditions characteristic of a heavily glycosylated glycoprotein and that this was slightly higher than the mass found for recombinant SICAM-1. The molecular mass range obtained is in the expected size range for monomeric SICAM-1 and is in agreement with previous results [1,31. Monomeric SICAM-1 idated from serum retained its ability to inhibit the binding of an anti-ICAM-1 MAb to ICAM-1 positive target cells. In contrast, physiological concentrations of monomeric ICAM-1 isolated from serum and urine failed to inhibit the LAK cell mediated cytolysis of four bladder tumour cell lines (Table 1) . However, sensitivity to lysis could be effectively blocked by the addition of antibodies to both ICAM-1 and LFA-1 demonstrating the importance of this adhesion pathway (Table 1) . It would therefore appear unlikely that the concentrations of SICAM-1 found in the urine following BCG immunotherapy could antagonise LFA-l/ICAM-1 mediated events in vivo in the bladder. 
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We have clearly demonstrated that highly purified SICAM-1 from a number of sources was unable to impair a highly LFA-l/ICAM-1 dependent cell-mediated cytotoxic process. These results provide further support to the recent observations which suggest that the monomeric form of SICAM-1 binds to its receptor LFA-1 with extremely low affinity [4,51.
